



BioPharmica Limited

16 March 2007

BioPharmica [ASX: BPH] ASX Release

NHMRC GRANT FUNDING AWARDED TO BIOPHARMICA PROJECT

Depth of Anaesthesia Monitor

BioPharmica is pleased to announce that BioPharmica's Cortical Dynamics project has been awarded an NHMRC Development Grant of \$182,500.

The grant will enable further commercial development and testing of a physiologically based anaesthesia monitoring process which monitors brain electrical activity. Assistance in the ongoing commercial development of this monitor will also involve the services of the leading biomedical product developer, Grey Innovation. The grant will be administered through Swinburne University under the control of Dr David Liley.

The research of Dr David Liley and his team, at Swinburne University of Technology (SUT), has resulted in a detailed understanding of the physiological mechanisms that generate surface recordable brain electrical activity known as the electroencephalogram (EEG).

The next step requires validation and further clinical testing of the prototype BAR (Brain Anaesthetic Response) monitor. Completion of this work will help the technology move into a commercially applicable device.

Cortical Dynamics, a company involved in the commercialisation of medical devices analysing brain electrical activity, began working with Dr Liley in 2004. Cortical Dynamics is an investee company of BioPharmica. The BAR system measures a patient's brain electrical activity (EEG) to indicate how deeply anaesthetised a patient is during an operation via an adhesive sensor applied to the forehead. This monitor is designed to assist anaesthetists and intensive care staff in ensuring patients do not wake up un-expectedly, as well as reducing the incidence of side effects associated with the anaesthetic. The BAR index operates through detailed understanding of the physiological mechanisms that generate EEG.

Market

The depth of the anaesthesia market including consumables is predicted by some to be worth USD750m by 2008. There are 50 million surgical operations worldwide per annum that require general anaesthesia. This provides a large commercial opportunity due to the growing medical and legal issues related to anaesthesia.

About BioPharmica Limited

BioPharmica [ASX: BPH] is an Australian Stock Exchange listed company developing biomedical research with academic and hospital institutes. The Company provides early stage funding for a direct collaboration, a spin out company or to secure a license. BioPharmica provides assistance with product development, funding and commercial strategies, whilst the institutional partner provides a majority of the infrastructure and research expertise.

MORE INFORMATION: Mr. Charles Murphy, Executive Director, Tel +61 8 9328 8366.

Yours faithfully

David Breeze
Chairman

BioPharmica Limited

ACN 95 912 002

PO Box 317, North Perth 6906, Western Australia

14 View Street, North Perth, Western Australia 6006

admin@biopharmica.com.au www.biopharmica.com.au

T: +61 8 9328 8366 F: +61 8 9328 8733